Skip to content

Hypertensive emergencies

TL;DR — The distinction that matters is not the number but whether acute end-organ injury is present. Where it is — malignant hypertension with retinal, cerebral, cardiac or renal microvascular damage — pressure must be lowered within hours, and non-adherence to an existing regimen is the commonest precipitant (Boulestreau 2024, PMID 38658108). Where it is not, the evidence points strongly the other way. Among 58,535 office presentations with systolic ≥180 or diastolic ≥110 mm Hg, propensity-matched patients sent home versus referred to hospital had no difference in major adverse cardiovascular events at 7 days, 8–30 days or 6 months, but more hospital admissions if referred; 64.6% of those sent home were still uncontrolled six months later (Patel 2016, PMID 27294333). In hospital, treating asymptomatic elevated pressure is associated with harm: intensive inpatient treatment of 66,140 older adults carried a weighted odds ratio of 1.28 (95% CI 1.18–1.39) for a composite of death, ICU transfer, stroke, acute kidney injury and biomarker elevation, rising to 1.90 (1.65–2.19) with intravenous agents (Anderson 2023, PMID 37252732). The 2026-09-01 searches located no randomised inpatient target trial with clinical outcomes.

Definitions

Term Definition Action
Hypertensive emergency Severe elevation with acute target-organ damage — encephalopathy, intracranial haemorrhage, acute coronary syndrome, acute heart failure/pulmonary oedema, aortic dissection, acute kidney injury, eclampsia, retinopathy grade III–IV Controlled parenteral or oral lowering over hours, in a monitored setting
Malignant hypertension / hypertension-MOD Emergency phenotype defined by acute microvascular damage and autoregulatory failure across retina, brain, heart, kidney and vasculature As above; a systemic disease, not a number (Boulestreau 2024, PMID 38658108; Cremer 2016, PMID 26582411)
Hypertensive urgency Severe elevation without acute target-organ damage Oral therapy, outpatient follow-up; hospital referral does not improve outcomes (Patel 2016, PMID 27294333)
Asymptomatic inpatient elevation Elevated readings during admission for an unrelated condition Observation and review of the outpatient regimen; treating is associated with harm (Anderson 2023, PMID 37252732; Rastogi 2021, PMID 33369614)

Malignant hypertension

Malignant hypertension is best understood as a systemic microvascular disease rather than a threshold crossing: both the absolute level and the rate of rise determine target-organ damage, because autoregulation adapts to chronic elevation but not to abrupt change (Boulestreau 2024, PMID 38658108). Non-adherence to existing therapy is the commonest cause; antiangiogenic (VEGF-pathway) and immunosuppressant drugs are recognised triggers (Boulestreau 2024, PMID 38658108; Grossman 2012, PMID 22195528). Direct biochemical assessment of adherence in emergency-department hypertensive crisis presentations confirms this (Wallbach 2019, PMID 30515967). Renal histology in hypertensive-emergency-related nephropathy shows the characteristic thrombotic microangiopathic picture (Nonaka 2013, PMID 23291673). Even with effective treatment, survivors remain at high cardiovascular and kidney risk, and outcome evidence is described by the authors themselves as "spotty or lacking" (Boulestreau 2024, PMID 38658108). Multiorgan involvement at presentation predicts prognosis (Ma 2020, PMID 32271999).

Urgency without organ damage

The Cleveland Clinic cohort is the reference dataset: 59,836 of 2,199,019 office visits (4.6%) met hypertensive-urgency criteria; mean systolic pressure 182.5±16.6 mm Hg. In the propensity-matched comparison of 852 sent home versus 426 referred to hospital, major adverse cardiovascular events were 0 versus 2 (0.5%) at 7 days, 0 versus 2 at 8–30 days, and 8 (0.9%) versus 4 (0.9%) at 6 months — no significant differences. Hospital admissions were higher in the referred group at 7 days (8.2% vs 4.7%) and 8–30 days (11.3% vs 6.9%) (Patel 2016, PMID 27294333). The clinically important number is the last one: two thirds of these patients were still uncontrolled six months later, which locates the real failure in longitudinal care rather than in the acute encounter. Emergency-department presentations with hypertension as the chief complaint rarely have serious outcomes (Frei 2013, PMID 24005086), and institutional pathways have been proposed to redirect them (Brody 2018, PMID 29637311).

Treating asymptomatic inpatient hypertension

Three large observational studies converge:

Study n Exposure Result
Rastogi 2021 (PMID 33369614) 22,834 non-cardiovascular medical admissions IV antihypertensive or new oral class Treated patients had more acute kidney injury (10.3% vs 7.9%) and myocardial injury (1.2% vs 0.6%); no blood-pressure interval in which treated patients did better; discharge intensification not associated with better control over the following year
Anderson 2023 (PMID 37252732) 66,140 veterans ≥65 hospitalised for non-cardiovascular diagnoses Intensive treatment after the first 48 hours Composite adverse outcome 8.7% vs 6.9% (weighted OR 1.28, 95% CI 1.18–1.39); IV agents OR 1.90 (1.65–2.19); consistent across age, frailty, prior pressure and cardiovascular history strata
Canales 2025 (PMID 39585709) 133,760 hospitalised veterans As-needed ("PRN") blood-pressure medication Acute kidney injury adjusted HR 1.23 (95% CI 1.18–1.29); >25% systolic fall within 3 hours 1.5-fold more likely (1.39–1.62); composite of MI, stroke or death 1.69-fold higher (1.49–1.92)

The mechanism proposed is abrupt reduction below the autoregulatory range in organs adapted to chronic elevation — supported by the dose-response with intravenous route and by the excess of rapid falls (Canales 2025, PMID 39585709). Quality-improvement work has reduced unnecessary intravenous treatment of asymptomatic elevation (Jacobs 2019, PMID 30811319), and as-needed intravenous therapy does not even achieve better blood-pressure control (Lipari 2016, PMID 26560085). All three outcome studies are observational with confounding by indication; the 2026-09-01 searches found emergency-department trials and a referral pilot but no randomised test of inpatient pressure treatment during a non-cardiac admission. Intensification of the outpatient regimen at discharge is separately associated with harm in older adults (Anderson 2018, PMID 30209052).

Situation-specific targets

The correct rate and depth of lowering is determined by the organ involved, and the evidence base sits mostly in other conditions' literatures:

  • Acute ischaemic stroke and intracerebral haemorrhage — permissive hypertension versus rapid lowering, thrombolysis and thrombectomy thresholds; see stroke. Post-endovascular-therapy targets have been meta-analysed (Zhang 2025, PMID 38557945), acute ICH lowering reviewed (Carandini 2018, PMID 28776173), and labetalol versus nicardipine compared in acute stroke (El-Ghoroury 2021, PMID 34217067); clevidipine has been studied against haematoma volume (Sterpi 2026, PMID 42397158).
  • Aortic dissection — the one setting demanding rapid, aggressive reduction of both pressure and the rate of pressure rise; see thoracic-aortic-aneurysm.
  • Acute heart failure with hypertension — afterload reduction is the therapeutic principle (Collins 2018, PMID 29478124); cardiac end-organ disease belongs to hypertensive-heart-disease.
  • Pre-eclampsia and eclampsia — severe hypertension in pregnancy is an emergency with its own drug set; see hypertension in pregnancy and (Murali 2020, PMID 32768095).
  • Posterior reversible encephalopathy syndrome — a distinct radiological-clinical syndrome, often but not always hypertensive, with its own management (Triplett 2022, PMID 35046115; Fischer 2017, PMID 28054130; Ando 2022, PMID 34275982; Gewirtz 2021, PMID 33630183; Halbach 2024, PMID 38727870; Li 2023, PMID 36464226; Jeelani 2022, PMID 35924741).

Reviews of initial drug management in emergencies are largely consensus-based (Strauss 2022, PMID 32940723; Ipek 2017, PMID 28306673; Aggarwal 2006, PMID 16326263; Feldstein 2007, PMID 17414580; Pak 2014, PMID 25598731), and a 2024 Philippine national guideline addresses acute severe elevation specifically (Ona 2026, PMID 41614648).

Epidemiology

Hypertensive crises are common presentations in low- and middle-income settings, where a large fraction are the first contact with care (Reis 2020, PMID 32776154; Kotruchin 2022, PMID 36196470). US national inpatient data show substantial admissions for hypertensive crisis with differences by race and sex (Nahle 2026, PMID 41543283).

Open questions

  • As of the 2026-09-01 PubMed and ClinicalTrials.gov searches, no randomised trial had established an inpatient blood-pressure target or an as-needed-treatment policy with clinical outcomes. Three large observational studies point toward harm from treating asymptomatic elevation and call for a trial (Rastogi 2021, PMID 33369614; Anderson 2023, PMID 37252732; Canales 2025, PMID 39585709).
  • What proportion of malignant hypertension is preventable by adherence support, given that non-adherence is the commonest precipitant? (Boulestreau 2024, PMID 38658108; Wallbach 2019, PMID 30515967)
  • Since two thirds of hypertensive-urgency patients remain uncontrolled at 6 months (Patel 2016, PMID 27294333), should the acute encounter be re-designed as an entry point into longitudinal care rather than a treatment episode?
  • Is there an evidence-based ceiling on the rate of blood-pressure reduction outside aortic dissection? The "25% in the first hour" convention is consensus, not trial-derived (Strauss 2022, PMID 32940723).
  • Does the association between as-needed medication and acute kidney injury reflect the drug, the rapid fall, or confounding by illness severity? (Canales 2025, PMID 39585709)

References

  1. Boulestreau R, et al. Malignant Hypertension: A Systemic Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2024;83:1688-1701. PMID 38658108
  2. Patel KK, et al. Characteristics and Outcomes of Patients Presenting With Hypertensive Urgency in the Office Setting. JAMA Intern Med. 2016;176:981-8. PMID 27294333
  3. Anderson TS, et al. Clinical Outcomes of Intensive Inpatient Blood Pressure Management in Hospitalized Older Adults. JAMA Intern Med. 2023;183:715-723. PMID 37252732
  4. Rastogi R, et al. Treatment and Outcomes of Inpatient Hypertension Among Adults With Noncardiac Admissions. JAMA Intern Med. 2021;181:345-352. PMID 33369614
  5. Canales MT, et al. As-Needed Blood Pressure Medication and Adverse Outcomes in VA Hospitals. JAMA Intern Med. 2025;185:52-60. PMID 39585709
  6. Cremer A, et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. 2016;30:463-6. PMID 26582411
  7. Grossman E, et al. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125:14-22. PMID 22195528
  8. Wallbach M, et al. Direct assessment of adherence and drug interactions in patients with hypertensive crisis. J Clin Hypertens. 2019;21:55-63. PMID 30515967
  9. Nonaka K, et al. Clinical and pathological evaluation of hypertensive emergency-related nephropathy. Intern Med. 2013;52:45-53. PMID 23291673
  10. Ma H, et al. Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study. J Clin Hypertens. 2020;22:914-923. PMID 32271999
  11. Frei SP, et al. Frequency of serious outcomes in patients with hypertension as a chief complaint in the emergency department. J Am Osteopath Assoc. 2013;113:664-8. PMID 24005086
  12. Brody AM, et al. Institutional Pathways to Improve Care of Patients with Elevated Blood Pressure in the Emergency Department. Curr Hypertens Rep. 2018;20:30. PMID 29637311
  13. Jacobs ZG, et al. Reducing Unnecessary Treatment of Asymptomatic Elevated Blood Pressure with Intravenous Medications. J Hosp Med. 2019;14:144-150. PMID 30811319
  14. Lipari M, et al. As-needed intravenous antihypertensive therapy and blood pressure control. J Hosp Med. 2016;11:193-8. PMID 26560085
  15. Anderson TS, et al. Intensification of older adults' outpatient blood pressure treatment at hospital discharge. BMJ. 2018;362:k3503. PMID 30209052
  16. Zhang K, et al. Intensive Versus Standard Blood Pressure Management after Endovascular Therapy for Acute Ischemic Stroke. J Neurosurg Anesthesiol. 2025;37:20-30. PMID 38557945
  17. Carandini T, et al. Intensive versus standard lowering of blood pressure in the acute phase of intracranial haemorrhage. Intern Emerg Med. 2018;13:95-105. PMID 28776173
  18. El-Ghoroury H, et al. Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine? J Stroke Cerebrovasc Dis. 2021;30:105959. PMID 34217067
  19. Sterpi AE, et al. Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage. Eur J Neurol. 2026;33:e70689. PMID 42397158
  20. Collins S, et al. Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction. Curr Hypertens Rep. 2018;20:9. PMID 29478124
  21. Murali S, et al. Preeclampsia, eclampsia, and posterior reversible encephalopathy syndrome. Handb Clin Neurol. 2020;172:63-77. PMID 32768095
  22. Triplett JD, et al. Posterior reversible encephalopathy syndrome (PRES): diagnosis and management. Pract Neurol. 2022;22:183-189. PMID 35046115
  23. Fischer M, et al. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264:1608-1616. PMID 28054130
  24. Ando Y, et al. Posterior Reversible Encephalopathy Syndrome: A Review of the Literature. Intern Med. 2022;61:135-141. PMID 34275982
  25. Gewirtz AN, et al. Posterior Reversible Encephalopathy Syndrome. Curr Pain Headache Rep. 2021;25:19. PMID 33630183
  26. Halbach SM, et al. Posterior Reversible Encephalopathy Syndrome in Children and Adolescents. Curr Hypertens Rep. 2024;26:349-354. PMID 38727870
  27. Li Y, et al. Posterior reversible encephalopathy syndrome and autoimmunity. Autoimmun Rev. 2023;22:103239. PMID 36464226
  28. Jeelani H, et al. Posterior Reversible Encephalopathy Syndrome in Organ Transplantation. Exp Clin Transplant. 2022;20:642-648. PMID 35924741
  29. Strauss M, et al. The hypertensive emergency situation: Recommendations for initial drug therapy management. Med Klin Intensivmed Notfmed. 2022;117:41-48. PMID 32940723
  30. Ipek E, et al. Hypertensive crisis: an update on clinical approach and management. Curr Opin Cardiol. 2017;32:397-406. PMID 28306673
  31. Aggarwal M, et al. Hypertensive crisis: hypertensive emergencies and urgencies. Cardiol Clin. 2006;24:135-46. PMID 16326263
  32. Feldstein C. Management of hypertensive crises. Am J Ther. 2007;14:135-9. PMID 17414580
  33. Pak KJ, et al. Acute hypertension: a systematic review and appraisal of guidelines. Ochsner J. 2014;14:655-63. PMID 25598731
  34. Ona DID, et al. Executive Summary of the 2024 Philippine Clinical Practice Guidelines on the Diagnosis and Management of Acute Severe Blood Pressure Elevation. J Clin Hypertens. 2026;28:e70199. PMID 41614648
  35. Reis KG, et al. Hypertensive Urgency in Tanzanian Adults: A 1-Year Prospective Study. Am J Hypertens. 2020;33:1087-1091. PMID 32776154
  36. Kotruchin P, et al. Hypertensive emergencies in Asia: A brief review. J Clin Hypertens. 2022;24:1226-1235. PMID 36196470
  37. Nahle T, et al. Inpatient Admissions for Hypertensive Crises in the USA by Race and Gender, 2016-2022. J Clin Hypertens. 2026;28:e70207. PMID 41543283